News

The boards of directors of both companies have approved the transaction. The purchase price is $29.5 million in cash plus the assumption of certain operating liabilities, subject to

The open-label, multi-center, dose-escalation, multi-dose Phase I clinical trial is expected to enroll up to 40 patients with advanced clear cell renal cell carcinoma (ccRCC) and is designed

The patent grants DiObex exclusive rights to methods of reducing the risk of hypoglycemia in diabetes patients being treated with insulin by administering very low doses of glucagon.

Under terms of the agreement, the company will acquire the right to develop, manufacture and market products and processes derived from Trophic’s patent, which relates to solutions containing

The round was led by Venture Investors, with participants including Advantage Capital, several Wisconsin based angel investor groups, and a large private equity firm. Cellectar will use the

The Phase II program is designed to evaluate the safety and efficacy of NKTR-102 (PEG-irinotecan) for the treatment of patients with solid tumors. The first study in the

The trial will investigate the efficacy and safety of Relaxin in patients with acute heart failure. Approximately 330 patients will be recruited from more than 50 investigational centers

The acquisition is expected to strengthen the company’s position in advanced in- vitro diagnostic (IVD) market in China. The company expects the acquisition to be accretive immediately from

Banner has developed and is in the process of registering the products for the US market, and under the agreements Heritage is granted exclusive sales and marketing rights